These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34001667)

  • 1. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.
    Liu K; Wang H; He W; Ye J; Song Y; Wang Y; Liu X; Wu Z; Chen S; Fan K; Liu Y; Zhang F; Li Z; Liu L; Zhang J; Zhang X; Ye J; Liang X; Li X; Ke X; Wu Q; Li J; Tao S; Wang X; Rosenfeld P; Heier JS; Kaiser P; Xu X
    Br J Ophthalmol; 2022 Oct; 106(10):1436-1443. PubMed ID: 34001667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
    Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
    Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
    Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
    JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
    Prünte C; Fajnkuchen F; Mahmood S; Ricci F; Hatz K; Studnička J; Bezlyak V; Parikh S; Stubbings WJ; Wenzel A; Figueira J;
    Br J Ophthalmol; 2016 Jun; 100(6):787-95. PubMed ID: 26453639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
    Xu Y; Rong A; Xu W; Niu Y; Wang Z
    BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.
    Li X; Dai H; Li X; Han M; Li J; Suhner A; Lin R; Wolf S;
    Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):529-541. PubMed ID: 30645696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
    Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
    Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
    Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
    Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.
    Li F; Zhang L; Wang Y; Xu W; Jiao W; Ma A; Zhao B
    Curr Eye Res; 2018 Feb; 43(2):218-223. PubMed ID: 29265939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and structural efficacy of a novel combinational therapy of aflibercept and timely focal/grid photocoagulation in diabetic macular oedema: do clinical study results compare favourably with a standard-of-care treated real-world population?
    Jørgensen MM; Vestergaard AH; Blindbaek SL; Peto T; Grauslund J
    Acta Ophthalmol; 2022 Dec; 100(8):e1624-e1629. PubMed ID: 35673897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
    Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.
    Lang GE; Berta A; Eldem BM; Simader C; Sharp D; Holz FG; Sutter F; Gerstner O; Mitchell P;
    Ophthalmology; 2013 Oct; 120(10):2004-12. PubMed ID: 23725735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
    BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial.
    Furashova O; Strassburger P; Becker KA; Engelmann K
    BMC Ophthalmol; 2020 Jul; 20(1):308. PubMed ID: 32727496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Efficacy of Intravitreal Conbercept Injections with or without Focal Macular Photocoagulation for Diabetic Macular Edema.
    Mao Y; Wang S; Ji X; Cao K; Hou S; Xiao Y
    Altern Ther Health Med; 2023 Jul; 29(5):308-313. PubMed ID: 37171942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.